{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:07Z","timestamp":1791348727039,"version":"4.3.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Urinary toxicities are common following prostate radiotherapy and can impair quality of life. New biomarkers are needed that can predict the risk of urinary toxicity following MRI guided stereotactic body radiotherapy (MR-SBRT) to assist with selection of the most appropriate radiotherapy treatment approach. We aimed to identify urine miRNA biomarkers of radiation-induced urinary toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ten patients undergoing MR-SBRT were enrolled on a prospective biorepository protocol and urine specimens were collected before, at the final fraction and 2-4 months following radiotherapy. RNA was isolated and microRNA sequencing was performed followed by qPCR for confirmation of microRNA expression changes. Differences in microRNA expression were assessed with regard to timepoint, cancer risk category and urinary toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both sequencing and qPCR showed that expressions of miR-26a-5p and miR-95-3p decrease during MR-SBRT and increase during early follow up. miR-204-3p and miR-192-5p changed differently in patients with and without urinary radiation toxicity. Expression of miR-375-3p was lower in patients with higher risk category (NCCN unfavorable intermediate to high risk or recurrent\/metastatic) at all timepoints and decreased during and after MR-SBRT, especially in patients with a lower risk category (NCCN low to favorable intermediate risk) of prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Urine microRNA analysis is feasible and may identify biomarkers linked to radiation-induced urinary toxicity and prostate cancer severity. The findings of this pilot study are limited by the sample size and should be prospectively validated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1951947","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:23Z","timestamp":1791348563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective pilot study of urine microRNA as a biomarker of urinary radiation toxicity following MRI-guided prostate stereotactic body radiotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Urszula","family":"Smyczy\u0144ska","sequence":"first","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Nowicka","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Doyle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejoo","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Dillon-Martin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanjan","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz","place":["Lodz, Poland"]},{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Leeman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.026","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"87","author":"Kishan","year":"2025","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ijrobp.2019.10.028","article-title":"Circulating microRNAs as biomarkers of radiation exposure: A systematic review and meta-analysis","volume":"106","author":"Ma\u0142achowska","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109731","article-title":"Serum miRNA-based signature indicates radiation exposure and dose in humans: A multicenter diagnostic biomarker study","volume":"185","author":"Nowicka","year":"2023","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.04.011","article-title":"Urine microRNAs as potential noninvasive biomarkers in urologic cancers","volume":"32","author":"Mlcochova","year":"2014","journal-title":"Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3951","article-title":"Validation and derivation of microRNA-based germline signatures predicting radiation toxicity in prostate cancer","volume":"31","author":"Kishan","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100934","article-title":"Magnetic resonance-guided prostate stereotactic body radiation therapy with daily online plan adaptation: Results of a prospective phase 1 trial and supplemental cohort","volume":"7","author":"Leeman","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12859-020-03743-8","article-title":"NormiRazor: tool applying GPU-accelerated computing for determination of internal references in microRNA transcription studies","volume":"21","author":"Grabia","year":"2020","journal-title":"BMC Bioinf"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084355","article-title":"Serum levels of miR-122-5p and miR-125a-5p predict hepatotoxicity occurrence in patients undergoing autologous hematopoietic stem cell transplantation","volume":"25","author":"Mikulski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa309","article-title":"miEAA 2.0: integrating multi-species microRNA enrichment analysis and workflow management systems","volume":"48","author":"Kern","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae Insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201902_16987","article-title":"MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt\/\u03b2-catenin pathway","volume":"23","author":"Xi","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.21037\/atm-22-5184","article-title":"MiR-95-3p acts as a prognostic marker and promotes cervical cancer progression by targeting VCAM1","volume":"10","author":"Feng","year":"2022","journal-title":"Ann Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/cgt.2016.2","article-title":"Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer","volume":"23","author":"Ma","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3892\/ijmm.2013.1360","article-title":"Utilization of microRNAs with decreased expression levels in response to X-ray irradiation for fine-tuning radiation-controlled gene regulation","volume":"32","author":"Morii","year":"2013","journal-title":"Int J Mol Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"287ra69","DOI":"10.1126\/scitranslmed.aaa6593","article-title":"Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury","volume":"7","author":"Acharya","year":"2015","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.07.014","article-title":"Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer","volume":"72","author":"Wang","year":"2011","journal-title":"Lung Cancer Amst Neth"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092068","article-title":"MiR-182-5p and miR-375-3p have higher performance than PSA in discriminating prostate cancer from benign prostate hyperplasia","volume":"13","author":"Abramovic","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41598-019-57101-7","article-title":"Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer","volume":"10","author":"Zedan","year":"2020","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000496206","article-title":"miR-192 is overexpressed and promotes cell proliferation in prostate cancer","volume":"28","author":"Chen","year":"2019","journal-title":"Med Princ Pract Int J Kuwait Univ Health Sci Cent"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109217","article-title":"The role of NLRP3 inflammasome activation in radiation damage","volume":"118","author":"Wei","year":"2019","journal-title":"BioMed Pharmacother Biomedecine Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34334","DOI":"10.1038\/s41598-025-16728-5","article-title":"Robustness of urinary extracellular vesicle-derived MiRNA profiles over multiple days and the impact of urine concentration","volume":"15","author":"Satomura","year":"2025","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2021.3243","article-title":"miRNA-877-5p inhibits Malignant progression of prostate cancer by directly targeting SSFA2","volume":"65","author":"Wang","year":"2021","journal-title":"Eur J Histochem EJH"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1989969","article-title":"microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1","volume":"12","author":"Yang","year":"2021","journal-title":"Bioengineered"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201805_15061","article-title":"MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma","volume":"22","author":"Yan","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5158-z","article-title":"Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1","volume":"37","author":"Guo","year":"2016","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1038\/s41598-022-08091-6","article-title":"MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A\/\u03b2-catenin signaling","volume":"12","author":"Chung","year":"2022","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21960","article-title":"MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1\/p53 pathway","volume":"8","author":"Shu","year":"2017","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01242","article-title":"MiR-204-3p inhibited the proliferation of bladder cancer cells via modulating lactate dehydrogenase-mediated glycolysis","volume":"9","author":"Guo","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1951947\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:30Z","timestamp":1791348570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1951947\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1951947"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1951947","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1951947"}}